JHC
ELVN icon

Jones Hill Capital’s Enliven Therapeutics ELVN Stock Holding History

Jones Hill Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Sell
49,850
-543,190
-92% -$23.1M 0.54% 26
2026
Q1 		$23.2M Buy
+593,040
New +$16.4M 4.98% 10

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jones Hill Capital's ELVN Position: Q2 2026 in Review

Jones Hill Capital reduced its Enliven Therapeutics (ELVN) stake by 92% in Q2 2026, selling an estimated $23.1M and leaving 49,850 shares worth $2.53M. The position accounts for 0.54% of the portfolio, ranked #26.

Jones Hill Capital first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. The position peaked at $23.2M in Q1 2026. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Jones Hill Capital held 49,850 shares of Enliven Therapeutics worth $2.53M as of Q2 2026.
  • Jones Hill Capital sold 543,190 Enliven Therapeutics shares in Q2 2026, an estimated $23.1M.
  • Enliven Therapeutics made up 0.54% of Jones Hill Capital's portfolio in Q2 2026, its #26 holding.
  • Jones Hill Capital first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Jones Hill Capital's Enliven Therapeutics position peaked at $23.2M in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.